All In Biotech

Drug Trial Radar · NCT03471871

Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea

A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea

Last checked: Nov 20, 2026Latest source record: Feb 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 146 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

146

Actual

Start

Feb 21, 2018

Primary completion

Aug 3, 2018

Study completion Aug 3, 2018

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
Collaborators
Purdue Pharma LP
First posted
Mar 21, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will be conducted to determine whether lemborexant as compared to placebo decreases the peripheral oxygen saturation during total sleep time in healthy adult and elderly participants after a single dose of treatment and to determine whether it increases the apnea-hypopnea index after single and multiple doses of treatment in adult and elderly participants with mild obstructive sleep apnea (OSA).

Conditions

  • Obstructive Sleep Apnea
  • Healthy Subjects

Interventions

  • PlaceboDrug

    HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).

  • Lemborexant 10 mgDrug

    HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).

  • Lemborexant 25 mgDrug

    HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).

  • PlaceboDrug

    OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.

  • Lemborexant 10 mgDrug

    OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HV Cohort: Peripheral Oxygen Saturation (SpO2) During Total Sleep Time (TST) on Day 1 of TreatmentTime frame: Day 1
  2. OSA Cohort: Apnea-Hypopnea Index (AHI) on Day 8 of TreatmentTime frame: Day 8

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • PACT

    Glendale, Arizona

  • Pulmonary Associates, PA

    Phoenix, Arizona

  • Pacific Research Network. LLC

    San Diego, California

  • PAB Clinical Research

    Brandon, Florida

  • Research Centers of America

    Hollywood, Florida

  • Neurotrials Research, Inc

    Atlanta, Georgia

  • The Center for Sleep & Wake Disorders

    Chevy Chase, Maryland

  • Advarra

    Columbia, Maryland

  • Clinilabs Drug Development

    New York, New York

  • CTI Clinical Research Center

    Cincinnati, Ohio

  • Community Research

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.